doi: 10.3389/fonc.2025.1640238 Received 03 June 2025 Accepted 06 October 2025 Published 17 October 2025 Volume 15 - 2025 Edited by Supriya Mallick, All India Institute of Medical Sciences, India Reviewed by Otvio da Cunha Ferreira Neto, University of So Paulo, Brazil Adila Amariyil, University College London Hospitals NHS Foundation Trust, United Kingdom Updates Copyright 2025 Wang and Zhang
M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Bifulco, M
A recent systematic review has documented this complementarity (McGuire et al., Curr Rev Musculoskelet Med 2025)
Therefore, to safely harness the attractive catabolic and thermogenic effects of glucagon for treating metabolic disease, a counter-balancing therapy that selectively opposes the risk for glucagon-induced hyperglycaemia is required